Oncology Products with Purpose
Development
Our innovative approach to solving problems in oncology and for orphan indications ensures we bring products to market that ease the burden of use for caregivers and enhance patient outcomes.
We are dedicated to developing novel products that are clinically impactful focusing on the pharmaceutical formulation to ensure high quality, greater dose flexibility, easier administration and better acceptance of medicines.
SH-105
Shorla Pharma have completed a successful pre-IND meeting with the US Health Authority, the Food and Drug Administration (‘FDA’) on our oncology drug SH-105. The FDA’s prompt and definitive response confirms our clinical and regulatory strategy and aligns with our plan to accelerate the filing of our New Drug Application (‘NDA’).
SH-110
Shorla Pharma have completed a successful pre-IND meeting with the US Health Authority, the Food and Drug Administration (FDA) on our third oncology drug SH-110. This proprietary product will have a significant benefit to patients suffering from brain cancer ultimately reducing treatment burden and providing a palatable age appropriate treatment.
SH-111
The successful GMP manufacture of Shorla’s first sterile oncology product was recently completed via state of the art robotic filling technology in our European GMP accredited partner facility. This important milestone will support the submission of Shorla’s imminent license application to the US FDA.
